Calcium Channel Blocker Comparison Tool

Select a drug to compare its characteristics with others:

Cardizem is a brand name for diltiazem, a non‑dihydropyridine calcium‑channel blocker that relaxes heart muscle and blood vessels. It’s prescribed for hypertension, stable angina and certain rhythm disorders. In the UK, Cardizem is available in immediate‑release tablets, extended‑release capsules and injectable form, each with distinct dosing patterns.

How Diltiazem Works

Diltiazem belongs to the calcium‑channel blocker class. By inhibiting L‑type calcium channels in cardiac and vascular smooth muscle, it reduces intracellular calcium, leading to decreased contractility and vasodilation. This dual action makes it useful for both lowering blood pressure and relieving angina‑related chest pain.

Key Clinical Indications

  • Hypertension - Diltiazem lowers systolic and diastolic pressures by relaxing arterioles.
  • Angina pectoris - It reduces myocardial oxygen demand by decreasing heart rate and contractility.
  • Atrial fibrillation/flutter - Slows AV‑node conduction, helping control ventricular rate.

Alternatives on the Market

When a clinician considers a calcium‑channel blocker, three other agents frequently surface: Verapamil, Amlodipine and the broader group of beta‑blockers. Each shares a basic vasodilatory or rate‑controlling effect but differs in selectivity, half‑life, and side‑effect profile.

Side‑by‑Side Comparison

Comparison of Cardizem (diltiazem) with major alternatives
Drug Class Typical Dose (adult) Half‑life (hrs) Primary Uses Key Contra‑indications
Diltiazem (Cardizem) Non‑dihydro‑Cav 1.2 blocker 30‑120mgER daily 3‑5 (ER)/6‑8 (IR) Hypertension, angina, AF rate control 2nd/3rd‑degree AV block, severe hypotension
Verapamil Non‑dihydro‑Cav 1.2 blocker 80‑240mgIR/ER daily 3‑7 Angina, SVT, hypertension Severe LV dysfunction, AV block
Amlodipine Dihydro‑Cav 1.3 blocker 5‑10mg daily 30‑50 Hypertension, chronic stable angina Severe hypotension, cardiogenic shock
Beta‑blockers (e.g., metoprolol) β1‑adrenergic antagonist 50‑200mg daily 3‑7 Hypertension, angina, heart failure Asthma, severe bradycardia, AV block
Safety Profile and Drug Interactions

Safety Profile and Drug Interactions

All calcium‑channel blockers share a risk of peripheral edema, headache and constipation, but the patterns differ. Diltiazem’s most common adverse events are flushing, dizziness and mild bradycardia. Verapamil tends to cause constipation more frequently, while amlodipine is notorious for ankle swelling.

One critical interaction hub is the CYP3A4 enzyme. Diltiazem is a moderate CYP3A4 inhibitor, meaning it can raise levels of statins (especially simvastatin), certain antivirals and other antihypertensives. When prescribing, clinicians often reduce the dose of a concomitant CYP3A4 substrate by 30‑50%.

Choosing the Right Agent: Decision Criteria

  1. Heart‑rate control needs: If slowing the AV node is a priority (e.g., AF), non‑dihydropyridines like diltiazem or verapamil are preferred over amlodipine.
  2. Comorbidity profile: Patients with chronic obstructive pulmonary disease (COPD) may tolerate diltiazem better than beta‑blockers, which can exacerbate bronchospasm.
  3. Drug‑interaction risk: For patients already on CYP3A4‑metabolised drugs, amlodipine (a weaker inhibitor) may be safer than diltiazem.
  4. Renal/hepatic function: Diltiazem’s hepatic clearance makes it unsuitable for severe liver disease; dose adjustment is needed in mild‑moderate hepatic impairment.
  5. Convenience: Once‑daily extended‑release formulations improve adherence for hypertension, while immediate‑release tablets are useful for acute angina episodes.

Related Concepts

Understanding the broader calcium‑channel blocker class helps clinicians anticipate cross‑reactivity and choose the best fit. The class splits into two major sub‑types: non‑dihydropyridines (diltiazem, verapamil) that affect cardiac conduction, and dihydropyridines (amlodipine, nifedipine) that mainly cause vasodilation. Other antihypertensive families-ACE inhibitors, ARBs, and diuretics-can be combined with calcium‑channel blockers for additive blood‑pressure control.

Practical Checklist for Prescribers

  • Confirm indication (HTN, angina, rate control).
  • Review current meds for CYP3A4 substrates.
  • Assess cardiac conduction (ECG) before starting non‑dihydropyridines.
  • Choose formulation (IR vs. ER) based on symptom pattern.
  • Set follow‑up: BP check in 2weeks, heart rate in 1week, labs for liver enzymes if high dose.

What’s Next?

If you’re a patient, discuss with your GP whether diltiazem matches your lifestyle and other meds. If you’re a clinician, consider the table above when drafting a treatment plan, and keep an eye on emerging data from the 2023 ESC hypertension guidelines which suggest preferring combination therapy early on. Future articles will dive deeper into managing calcium‑channel blocker‑induced edema and switching strategies between agents.

Frequently Asked Questions

Frequently Asked Questions

What makes Cardizem different from other calcium‑channel blockers?

Cardizem (diltiazem) is a non‑dihydropyridine agent that not only dilates vessels but also slows heart‑rate and AV‑node conduction. This dual effect makes it useful for both hypertension and rhythm disorders, whereas dihydropyridines like amlodipine mainly act on vessels.

Can I take Cardizem with a statin?

Because diltiazem inhibits CYP3A4, it can raise levels of statins metabolised by the same pathway (especially simvastatin and lovastatin). Your doctor may lower the statin dose or switch to a CYP3A4‑independent statin like pravastatin.

Is the extended‑release form better for blood‑pressure control?

Yes, the ER capsule provides a steadier plasma concentration over 24hours, improving adherence and delivering more consistent BP reduction compared with multiple daily immediate‑release tablets.

What are the main side effects I should watch for?

Common issues include headache, flushing, mild dizziness and peripheral edema. Rarely, patients develop severe bradycardia or heart‑block; any sudden fainting or palpitations should prompt medical review.

When is a beta‑blocker a better choice than Cardizem?

Beta‑blockers excel when a patient needs both rate control and myocardial oxygen‑use reduction, especially post‑myocardial infarction or in heart‑failure with reduced ejection fraction. They also avoid CYP3A4 interactions seen with diltiazem.

Can I switch from amlodipine to Cardizem without a wash‑out period?

Because the two drugs work via different calcium‑channel subtypes, a short overlap is usually safe, but clinicians often taper amlodipine over a week while initiating diltiazem to avoid additive hypotension.